Day: August 10, 2022

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 Announced positive topline results from Phase 2 trial of Zygel in patients with 22q11.2 deletion syndrome (22q) Company focusing resources on orphan neuropsychiatric disorders, FXS and 22q $62.5 million in cash and cash equivalents at June 30, 2022; Cash runway through the end of 2023 / early 2024 DEVON, Pa., Aug. 10, 2022 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reported financial results for the second quarter ended June 30, 2022, and provided an overview of recent operational highlights and a pipeline update. “During...

Phase 1 umbrella trial for hematologic malignancies open for enrollment Publication in Cell further validates use of foundational technology to identify novel tumor antigens and effective TCRs TSC-200-A2 (HPV) and TSC-204-C7 (MAGE-A1) IND filings anticipated by year-end 2022 Appointment of Debora Barton, M.D., as Chief Medical Officer Ended quarter with cash and cash equivalents of $125.6 million, funding operations into 2024 WALTHAM, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results for the second quarter ended June 30, 2022 and provided business updates. “During the second quarter we have made...

– Patients with MTAP-deleted solid tumors being actively enrolled in ongoing Phase 1/2 trial of TNG908, an MTA-cooperative PRMT5 inhibitor – – Received Orphan Drug Designation in US for the treatment of malignant peripheral nerve sheath tumors with TNG908 – CAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the second quarter ended June 30, 2022 and provided business highlights. “We are continuing to advance our lead MTA-cooperative PRMT5 inhibitor program, TNG908, as we actively enroll patients with MTAP-deleted solid tumors in an ongoing Phase 1/2 trial,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics....

Second Quarter Net Sales Increased +13% to $115 million; For The First Six Months, Net Sales grew +19% Gross Margin of 25% Represents a Sequential Improvement of Over 500 Basis Points from the First Quarter Company Reaffirms Previously Communicated Net Sales and Adjusted EBITDA Guidance NEW YORK, Aug. 10, 2022 (GLOBE NEWSWIRE) — The Vita Coco Company, Inc. (NASDAQ: COCO) (“Vita Coco” or the “Company”), a leading high-growth platform of better-for-you beverage brands, today announced financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Highlights Compared to Prior-Year PeriodNet sales grew 13% to $115 million driven by strong 21% growth of Vita Coco Coconut Water which continues to be the largest contributor to growth on a consolidated basis.Gross profit was $29 million, flat on a dollar basis,...

Completed agreement for strategic collaboration to jointly develop and commercialize CLN-081 with Taiho Pharmaceutical Presented updated Phase 1/2a data for CLN-081 at the 100mg BID dose showing median duration of response greater than 21 months and median progression-free survival of 12 months at the American Society for Clinical Oncology (ASCO) Annual Meeting Cash and investments of $656 million1 as of June 30, 2022 expected to provide runway through 2026. CAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapeutic candidates across multiple modalities for patients with cancer, today reported on recent and upcoming business highlights and announced its financial results for the second quarter ended June...

Sales increased to $907 million, despite the normalization of residential lumber sales 10% organic growth for infrastructure-related businesses EBITDA(1) of $154 million, or a healthy margin of 17.0% Net income of $94 million, or $1.51 per share Strong cash flow generation of $228 millionMONTREAL, Aug. 10, 2022 (GLOBE NEWSWIRE) — Stella-Jones Inc. (TSX: SJ) (“Stella-Jones” or the “Company”) today announced financial results for its second quarter ended June 30, 2022. “Stella-Jones recorded solid results in the second quarter, above market performance, delivering sequentially higher margins and generating significant cash,” said Éric Vachon, President and CEO of Stella-Jones. “We are particularly pleased with the performance of our infrastructure-related businesses, which speaks highly to the wide reach of our expanded network...

Expanded DNA oncology vaccine program into non-small cell lung cancer, NSCLC Announced successful production of personalized cancer immunotherapies for melanoma Announced gonorrhea as second bacterial product target Ended second quarter with cash and cash equivalents of $25.3 million Evaxion will host webcast and conference call today, August 10, at 8:30 am EDTCOPENHAGEN, Denmark, Aug. 10, 2022 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today its second quarter 2022 financial results and provided an operational and business update. Lars Wegner, CEO of Evaxion, said: “Evaxion announced multiple exciting milestones in the second quarter of 2022. We expanded our DNA oncology vaccine...

BRANFORD, Conn., Aug. 10, 2022 (GLOBE NEWSWIRE) — IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today reported financial results for the quarter ended June 30, 2022. Recent HighlightsDrove operational efficiencies and headcount reductions through our Reduction in Force (RIF) resulting in a $4.3 million reduction in operating expenses compared to Q1 2022, representing a 14% reduction which includes $3.7 million of nonrecurring restructuring expense.Revenue of $4.0 million for the second quarter 2022, representing a 7% decrease from the corresponding period of 2021Trailing twelve months revenue of $18.7 million represents a 31% increase vs the prior year periodSold 20 new instruments in the second quarter, bringing the installed base...

Signed Exclusive Licensing Agreement for Commercialization of D-PLEX100 in Europe for Potentially Over $110 Million in Upfront and Milestone Payments, Plus Royalties on Net SalesIndependent Data Safety Monitoring Board Recommended Concluding Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery Following Enrollment of the Minimum Number of Targeted PatientsConcluded Enrollment in Phase 3 SHIELD I TrialTop-line Results from the Phase 3 SHIELD I Trial Anticipated by End of Q3 2022Conference Call Scheduled for Today at 8:30 AM ETPETACH TIKVA, Israel, Aug. 10, 2022 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and six months ended...

HANGZHOU, China, Aug. 10, 2022 (GLOBE NEWSWIRE) — Nano Labs Ltd (Nasdaq: NA) (“we,” the “Company” or “Nano Labs”), a leading fabless integrated circuit design company and product solution provider in China, today announced its unaudited financial results as of June 30, 2022 and for the first half of 2022 then ended. First Half of 2022 Financial HighlightsNet revenue increased significantly to RMB380.1 million (US$56.6 million) from RMB22.8 million in the same period of 2021. Gross profit increased significantly to RMB176.4 million (US$26.3 million) from RMB11.2 million for the same period of 2021. Profit from operations was RMB107.6 million (US$16.0 million) for the first half of 2022, compared to a loss from operations of RMB34.2 million in the same period of 2021. Net income was RMB111.4 million (US$16.6 million) for the first...